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PLASMAPHERESIS IN NEUROLOGIC DISORDERS
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SUMMARY - Two decades after the initial encouraging reports on plasmapheresis in myasthenia
gravis, neurologic diseases represent the most common indication for therapeutic plasma exchange.
Recent studies have not only established the therapeutic importance of plasmapheresis, but have also
set new standards for the management of autoimmune neurologic disorders. Plasmapheresis has proved
beneficial in autoimmune neurologic diseases such as Guillain-Barre syndrome, myasthenia gravis,
and paraprotein-associated polyneuropathy. In some other diseases, e.g., multiple sclerosis, polymyo-
sitis, dermatomyositis, and chronic inflammatory demyelinating polyneuropathy, plasmapheresis
cannot be considered a generally accepted therapeutic option. However, in chronic autoimmune dis-
eases such as progressive multiple sclerosis, polymyositis, dermatomyositis, and chronic inflamma-
tory demyelinating polyneuropathy, plasmapheresis is recommended in patients whose condition
continues to worsen despite immunosuppressive drug therapies, and in those for whom it is desirable
to reduce the dose of corticosteroids to avoid long-term complications. Based on the initial studies,
plasmapheresis in conjunction with immunosuppressive drug therapies is now standard therapy for
Eaton-Lambert syndrome.
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The initial encouraging report by Dau et al.1 on plas-
mapheresis (PP) in myasthenia gravis (MG) published
more than two decades ago led to unprecedented interest
in and hope for various neurologic disorders with pre-
sumed autoimmune dysfunction. Within a few years, there
were many anecdotal and pilot studies to warrant con-
trolled trials of PP in neurologic disorders such as MG,
Guillain-Barre syndrome (GBS), multiple sclerosis (MS),
and chronic inflammatory demyelinating polyneuropathy
(CIDP). These studies have established the therapeutic
importance of PP and set new standards for clinical trials
in autoimmune neurologic disorders2. A pilot of an inter-
national therapeutic apheresis registry was conducted by
the International Center for Artificial Organs and Trans-
plantation for the year 1983 to collect data on PP proce-
dures and technology3. In this voluntary survey, a 24.1%
response rate was received by the centers solicited. Thirty-
seven centers on four continents reported data on 659
patients receiving 5,780 PP. In the East (Asia and Aus-
tralia), digestive system diseases were the most commonly
reported treatment diagnosis, whereas in Europe and USA
neurologic disorders prevailed4.
The aim of this report is to provide an overview of the
current trends and practice of PP in neurologic disorders.
Myasthenia Gravis
Myasthenia gravis (MG) is a chronic disease that most
commonly occurs in young adults and progresses with
remissions and exacerbations. It is characterized by the
activity-induced abnormal muscle fatigability resulting in
typical drooping of eyelids and jaws, nasal voice, slurred
speech, and weakness of proximal extremities. MG in-
volves progressive failure of impulse conduction at the
neuromuscular junction. It is an antibody-mediated au-
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toimmune disease in which circulating acetylcholine re-
ceptor (AChR) antibodies have been identified that bind
to receptor sites in voluntary muscles, damaging and
blocking the receptors5. Hyperplasia of the thymus is fre-
quently associated, and approximately 12% of patients
with MG have a thymoma.
During the early active stage of MG while the char-
acteristic remissions and exacerbations occur and before
muscle atrophy has set in, some patients may respond well
to surgical removal of the thymus. Many balieve that early
thymectomy may decrease the level of autoimmune activ-
ity before a major permanent damage has been sustained
by the AChR sites in voluntary muscles. Steroids are usu-
ally given to suppress the production of antibodies, and
azathioprine was found useful in some cases2. Anticho-
linesterase drugs are administered to prevent the break-
down of acetylcholine at the myoneuronal junction.
The initial and ground-breaking study by Dau et al.1
established the efficacy of PP in MG patients, and led to
further confirmatory clinical trials6-8. The response to PP
in these studies was so dramatic, that there has never been
felt the need of a double-blind randomized controlled study
since. In spite of this, the 1985 NIH Consensus Conference
concluded that PP could be useful in increasing muscle
strength during the pre- and post-thymectomy period, and
in decreasing the symptoms associated with the initiation
of immunosuppressive therapy and during acute crises9.
In acute myasthenic crisis, the recommended PP pre-
scription is five sessions over a one-week period. Each
session should be equal to 1.5 plasma volume (PV), which
can be replaced with 5% albumin (Table 1). If the patient
is in the immediate prethymectomy period, partial replace-
ment of approximately 1 L of fresh frozen plasma (FFP),
given toward the end of the last session, should help re-
verse the expected depletion coagulopathy10. PP therapy
is then gradually decreased as tolerated by the patient.
Although the levels of AChR antibodies are unlikely to
be immediately available for therapy monitoring, a retro-
spective comparison between the observed and expected
declines in AChR antibodies reveal an excellent correla-
tion with the calculated total IgG removal kinetics11.
In patients with MG who need continued immuno-
suppressive drug therapy (ISDT), weekly PP therapy with
gradual reduction in conventional ISDT (prednisolone,
azathioprine, and cyclophosphamide) is recommended.
Once the desired dosage of ISDT has been reached, the
frequency of PP is gradually decreased, and patients are
eventually weaned. In a small number of patients, main-
tenance PP therapy may become necessary for a long pe-
riod of time (up to several years)2. In some patients in
whom PP and conventional ISDT either cannot be de-
creased or the patient cannot be successfully weaned, the
addition of a low dose cyclosporin (1 to 5 mg/kg body
weight/day) is effective12.
Table 1. Plasmapheresis in patients with myasthenia gravis
Indications
Patients with severe motor weakness not responding to conventional therapy
Patients with myasthenia gravis who may need surgery
Assessment of response
Motor strength with and without physostigmine
Acetylcholine receptor antibody titer change
Suggested therapy
1.5 PV sessions daily for 5 days
Replacement of removed plasma ml/ml with 5% albumin
Precautions
Acetylcholine receptor antibody titer does not correlate with disease severity, but
relative changes do
Intervention in patients with chronic disease does not produce sustained improve-
ment
Anticholinesterase medication given during plasmapheresis may cause cholinergic
reactions consisting of bradycardia, abdominal cramping, sweating, and hypoten-
sion or respiratory arrest
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There have been no controlled studies showing the
significant effect of intravenous immune globulin (IVIG),
but this therapy was used with good results in some stud-
ies13,14. The ease of administration and lack of significant
side effects make IVIG a good chance, either alone or in
combination with PP as dictated by the disease severity2.
Guillain-Barre Syndrome
(Acute Idiopathic Polyneuritis)
Guillain-Barre syndrome (GBS), an acute, frequently
postinfection (but may also occur after vaccination, injury,
or surgery) polyneuritis may be due to an allergic response
or some type of hypersensitivity reaction. Demyelination
and degeneration of the myelin sheath and axon occur in
the segmental peripheral nerves, and in the anterior and
posterior spinal nerve roots. Antibodies directed against
various constituents of peripheral myelin have been iden-
tified15. Inflammation, edema, and damaged nerves result
in both sensory and motor dysfunction (the muscles of the
trunk and upper extremities). The diagnosis is supported
by the existence of an albuminocytologic dissociation in
the cerebrospinal fluid16.
The treatment with steroids, ISDT, may or may not
be beneficial in altering the course of the disease. The fa-
vorable outcome in earlier case reports on PP in acute
GBS17-19 led to three large randomized controlled trials,
which for the first time firmly established an effective
treatment for this disease21,22. The most compelling evi-
dence for the efficacy of PP come from a multicenter study
involving 21 medical centers and 245 patients with GBS,
randomized to either supportive therapy or PP21. The
patients receiving PP had a substantially reduced duration
of muscular weakness (40 vs. 29 days) and required a sig-
nificantly shorter period of pulmonary support (48 vs. 24
days)21. It should also be noted that a British randomized
trial failed to conlude on the beneficial effects of PP in
GBS23.
In patients with a second-grade or worse GBS (de-
monstrable weakness in the legs, but able to walk 5 m
without a walker or equivalent support)24, PP should be
initiated as early as possible. The recommended PP pre-
scription is a total of 10 one-PV exchanges (at least 200
to 250 ml of plasma/kg body weight) delivered over a
period of 14 days (Table 2). An increased frequency in the
beginning of treatment, followed by PP procedure per-
formed on alternating days is recommended25. The total
Table 2. Plasmapheresis in patients with Guillain-Barre syndrome
Indications
Ascending paralysis involving upper extremities or higher level
Decrease in pulmonary function parameters (1-min forced expiratory volume or
vital capacity) to 80% of normal
Respirator dependence
Infusion of intravenous immunoglobulins only (without plasmapheresis) is also ef-
ficacious therapy
However, although not statistically significant, patients randomized to plasmapher-
esis were started on therapy later and were sicker
Assessment of response
Neurologic assessment
Measure the forced expiratory volume at 1 min (FEV 1.0) and vital capacity every
12 hours
Suggested strategy
1-PV session daily for 5 days; then five more 1-PV sessions every other day
Replace removed plasma with 5% albumin ml/ml during the first 3 to 4 sessions;
for subsequent sessions, replace a half of the removed plasma volume with FFP in-
stead of 5% albumin
Continue the treatment if the patient is still respirator dependent
Intravenous infusion of IgG (40 g) at the end of treatment may be beneficial
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number of PP therapies required to improve and stabilize
a GBS patient may vary from 5 to more than 15 sessions2.
A recent Dutch study compared the accepted PP regi-
men with IVIG, demonstrating a better or at least equal
outcome with IVIG26. An accompanying review has
found these results difficult to interpret because the pa-
tients treated with PP worsened more than expected15.
Most recently, a comprehensive comparison of IVIG and
PP for neurologic diseases has suggested that those receiv-
ing IVIG may have a tendency to relapse27.
Chronic Progressive Multiple Sclerosis
Mulitple sclerosis (MS) is a relatively common chronic
and progressive inflammatory, demyelinating disease of the
central nervous system that results in diverse manifestations
of neurologic alteration. Its basic cause is unknown, how-
ever, it is probably an autoimmune disorder influenced by
genetic susceptibility. Studies of antibodies in the blood or
cerebrospinal fluid often show gammaglobulin abnormali-
ties.The oligoclonal bands of IgG directed against the vari-
ous antigens of the measles virus but no specific antigen
have been isolated in multiple sclerosis28.
The treatment of multiple sclerosis is generally symp-
tomatic, because immunosuppression using steroids, aza-
thioprine and cyclophosphamide has provided encourag-
ing results25,29. A larger study in which a prolonged PP
protocol was used in patients taking cyclophosphamide and
prednisone, showed a significant and sustained improve-
ment in 62.2% of patients30. Clinical improvement was
associated with improvement in evoked potential studies
and suppressor cell functional activity in these patients.
Although ISDT alone has in various studies stabilized or
even brought about some improvement in MS31,32, the re-
sults of this analysis indicate that the degree of improve-
ment and the length of disease stabilization is greater when
PP is added to ISDT. An overall review of ISDT in MS
leads to a conclusion that in an attempt to achieve short-
term stabilization in the course of the disease, the dosage
of the cytotoxic drug must be high and booster therapies
are required, or therapy has to be continued for a long time2.
In such a setting, the side effects of ISDT (alopecia, carci-
noma) are of great concern32,33.
Results of a previous study30 suggest combining ISDT
with an extended use of PP not only to achieve improve-
ment and longer stabilization of the course of the disease,
but also to use a potentially less toxic short course of low
dose ISDT. In 200 MS patients who received PP and such
a short course of low dose ISDT, Khatri et al.34 did not
record any serious side effects with the exception of one
patient who manifested carcinoma of the breast 3 years
after discontinuation of cyclophosphamide (this incidence
is lower than the natural incidence of breast carcinoma).
Even more, MS patients who received PP and ISDT
showed a significant (p<0.001) improvement at therapy
completion, and at one-, two- and three-year follow-up34.
Over 80% of patients improved or stabilized at 3 years
following PP and ISDT. The analysis of various clinical
characteristics in those who improved after this therapy
failed to show any differences according to gender, age at
onset, or degree of disability at the time of treatment.
Statistically significant (p<0.001) differences were ob-
served in age at the time of treatment and total duration
of the disease. The improvement was better in younger
patients with shorter duration of MS. The degree of de-
cline on the disability status scale (DDS) relative to the
time of therapy introduction also was a significant pre-
dictor of improvement. Seventy-five percent of MS pa-
tients who improved were treated within a year from the
time of their decline on DDS by one or more degrees34.
The mean number of PP administered during the initial
course of treatment was 24 (range, 12 to 46). Forty-three
(21.5%) patients received more than one course of PP
during the follow-up. These patients had initially im-
proved and stabilized, whereafter their condition began to
worsen at a variable time after the initial course of PP. A
short course of PP (5 weekly sessions) restored or stabi-
lized improvement in 81.4% of patients. Coadministration
of drug therapy during retreatment consisted of pred-
nisone (0.5 mg/kg body weight every other day) in de-
creasing dosages, and human IgG injections after each PP.
The response to retreatment was as good as the response
to the initial course. According to Khatri et al.34, it is pos-
sible to predict the outcome of MS patients treated with
PP and ISDT. Table 3 presents expected improvement in
DDS following PP and ISDT, while Table 4 shows
chances for patient improvement by one or more de-
grees34.
Recently, the Canadian Multicenter Cooperative
Study randomized 168 patients to cyclophosphamide and
prednisone with or without weekly PP or placebo medi-
cation and sham PP35. After approximately 20 weeks of
active treatment, the patients were monitored for disability
scores for a mean of 30-month follow-up. In the PP
group, a trend of decreasing disability was observed at 12,
18 and 24 months of the follow-up, however, the differ-
ence was not sustained at 36 months35.
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In a pilot study, PP along with recombinant alpha in-
terferon produced a significant improvement in 21 of 24
patients with progressive MS36.
The exact mechanism of PP action in progressive MS
is not known. According to one hypothesis, the improve-
ment in the functional activity of suppressor T cells fol-
lowing PP is associated with clinical improvement in pro-
gressive MS31. Another hypothesized mechanism involves
removal of circulating toxins, antigens, or antibodies that
acutely damage myelin sheaths or oligodendrocytes37.The
removal of the interferon inhibiting factor by PP therapy
can result in increased circulating interferon alpha con-
centrations, and a significant clinical improvement38.
At present, PP cannot be considered a generally ac-
cepted therapeutic option for MS2,25. The Writing Com-
mittee of the American Society for Apheresis recom-
mends the use of PP in chronic progressive MS when
conventional therapy has failed to either stop the progres-
sion of the disease, or to improve patient condition as well
as when conventional therapy is contraindicated39. The
recommended protocol is one PV PP per week for 10
weeks in conjunction with prednisone (1 mg/kg body
weight every other day) and cyclophosphamide (1 mg/kg
body weight/day). If the patient shows objective improve-
ment, PP and ISDT are tapered over time until patient
stabilization is achieved (mean, up to 20 PP sessions). A
Table 3. Expected change on disability status scale in patients with chronic progressive multiple sclerosis
following plasmapheresis and immunosuppressive drug therapies35
Patient age Worse by ³ 1 DSS Worse by <1 DSS
 (yrs) in previous year in previous year
Duration of multiple sclerosis (yrs)
<3 3-7 >7 <3 3-7 >7
<33 3.9 1.7 1.5 2.2 0.6 0.1
33-40 1.9 0.8 1.2 1.1 0.6 0.2
>40 1.2 2.5 1.0 0.8 0.5 0.4
Bootstrap standard errors
<33 0.7 0.4 0.8 0.8 0.3 0.1
33-40 0.6 0.2 0.3 0.5 0.2 0.1
>40 0.6 0.4 0.2 0.5 0.2 0.1
Table 4. Chance for one or more step improvement on disability status scale in patients with chronic pro-
gressive multiple sclerosis following plasmapheresis and immunosuppressive drug therapies35
Patient age Worse by ³ 1 DSS Worse by <1 DSS
(yrs) in previous year in previous year
Duration of multiple sclerosis (yrs)
<3 3-7 >7 <3 3-7 >7
% % % % % %
<33 95 86 68 76 36 26
33-40 66 77 63 56 76 20
>40 77 95 77 55 54 39
Bootstrap standard errors
<33  5 14 30 16 19 17
33-40 15 24 12 20 16 13
>40 23  5 12 17 14  7
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small group of MS patients may need maintenance the-
rapy once every 6 to 10 weeks, with or without predni-
sone39. PP therapy is discontinued if no objective impro-
vement is observed at the end of 10-week treatment.
Chronic Inflammatory Demyelinating
Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is believed to be an autoimmune disease, and is
characterized by a progressive or relapsing course, sym-
metrical motor or motor and sensory loss, hyporeflexia or
areflexia, and absence of systemic symptoms. Humoral
and cellular immune dysfunctions have been implicated
in the pathogenesis of CIDP40. Abnormalities support-
ing the diagnosis include elevated cerebrospinal fluid pro-
tein, severe slowing of nerve conduction velocity, and seg-
mental demyelination on nerve biopsy. The condition can
progress to severe disability or death41.
A potential benefit from plasma exchange therapy has
previously been reported from several uncontrolled stud-
ies4. The most convincing data come from a randomized,
sham-controlled trial in severely affected patients40.Treat-
ment prescription included 2 PV exchange procedures per
week for 3 weeks. Each plasma exchange averaged 1 to 1.5
PV, and replacement fluid was 5% albumin. Approxi-
mately 30% of those treated with PP responded with
improved DDS and nerve conduction. There was no pro-
spective means of identifying the responders. In those
patients who responded, improvement generally began to
fade within 10 to 14 days after the treatment discontinu-
ation, suggesting that a maintenance treatment schedule
may be required to sustain remission. This study firmly
established the usefulness of PP in CIDP41. While ISDT
has been recommended in CIDP, in those patients who
do not respond adequately or need long-term ISDT, PP
should be considered. As CIDP is a chronic disease, PP
needs to be combined with ISDT. The dosages and du-
ration of ISDT are much lower when therapies are used
in combination with PP41. A recent report has established
the need of long-term treatment of CIDP with PP43.
Indeed, a preliminary report by Feasby et al.44 shows that
maintenance of neurologic improvement required PP to
be performed at a schedule ranging from weekly to every
3 weeks for up to 60 months.
Khatri and Wroblewski45 have reported on a retro-
spective study in 31 patients with CIDP resistant to con-
ventional therapy, who were treated with PP. In most of
these patients, PP produced significant improvement,
however, 11 (35.5%) patients required continued PP
therapy (mean, 3.6 years). A majority of the remaining 20
(64.5%) patients who were successfully weaned from PP,
required at least 12-month treatment45.
Dyck et al.46 randomized and treated 20 CIDP pa-
tients with either PP or IVIG for 6 weeks, followed by
washout period, and then switched to another treatment.
The PP treatment protocol included 2 PP sessions a week
for 3 weeks, then once a week for the next 3 weeks. Ac-
cording to the IVIG protocol, CIDP patients received
immune globulin (0.4 g/kg body weight) once a week for
3 weeks, then 0.2 g/kg body weight once a week for the
next 3 weeks. In both the PP and IVIG treated group of
CIDP patients, a statistically significant improvement
occurred in DDS and summation compound muscle ac-
tion potentials (p<0.001)46. In another open study in 67
consecutive CIDP patients, the response rates were similar
in the ISDT, IVIG and PP treated patients, whereas func-
tional improvement was greatest in the group of patients
treated with PP47.
In CIDP patients, the PP therapeutic protocol is in-
dividually tailored according to the disease severity. Most
patients are initially treated with ISDT, and PP is only
initiated when there is no response to previous therapy, or
if it appears that the patient may need a high dosage long-
term steroid therapy. Minors receive PP twice a week for
3 weeks, then once a week for 3 weeks. If objective im-
provement is noted, PP is continued to be tapered until
the patient can be safely weaned from treatment2. In pa-
tients without objective improvement after the initial 9 PP
sessions as well as in those who cannot be weaned from
PP, the addition of ISDT or IVIG should be considered.
Patients with a severe form of CIDP may need to be
treated with maintenance long-term PP with or without
ISDT or IVIG therapy2.
Paraprotein-associated Polyneuropathy
The presence of monoclonal antibodies (IgM, IgA,
and IgG) may be associated with antibody binding to
certain constituents of peripheral myelin and consequen-
tial neuropathy. Cellular immune dysfunction has also
been implicated in the pathogenesis of this syndrome. A
demyelinating process is characterized by distal weakness,
tremor, ataxia and loss of perception30. The cancer usu-
ally remains localized, but the patients die from neurologic
dysfunction.
P. Kes and V. Ba¹iÊ Plasmapheresis in neurologic disorders
Acta clin Croat, Vol. 39, No. 4, 2000 243
Removal of these immunoglobulins is the rationale for
PP therapy. In a randomized, sham-controlled trial in
patients with paraprotein-associated polyneuropathy,
Dyck et al.48 found that sensorimotor neuropathy im-
proved significantly in patients receiving PP. The treat-
ment prescription was 2 PP weekly for 3 weeks. Each
plasma exchange averaged 3.5 L, and replacement fluid
was 5% albumin48. Further investigation is warranted to
determine the role of aggressive PP in conjunction with
ISDT in paraprotein-associated polyneuropathy.
Eaton-Lambert Syndrome
Eaton-Lambert syndrome (ELS) is a myasthenia-like
syndrome, clinically manifested with proximal muscle
weakness, easy fatigability, and autonomic dysfunction. It
may be cancer-related or idiopathic. Pathophysiologically,
it is the result of antibody-mediated blockage of acetyl-
choline release by the presynaptic nerve terminal, causing
disruption of calcium channels, which in turn leads to a
decreased calcium flux across the membrane. The humoral
and cellular immune dysfunction has been implicated in
the pathogenesis of ELS, and in 70% of patients the dis-
ease is associated with cancer (usually an oat cell carci-
noma of the lung)49.
Dau and Denys50 describe clinical and electromyo-
graphic improvement in patients treated with PP. The
underlying tumor must also be treated.
Based on the initial studies50,51, PP should be carried
out twice weekly for 3 weeks, then weekly for 3 weeks,
followed by a gradual weaning process. PP therapy is usu-
ally combined with ISDT (azathioprine 1-2 mg/kg body
weight/day, and prednisolone in a dose of 1 mg/kg body
weight/day) in a declining fashion2.
Polymyositis and Dermatomyositis
Polymyositis (PM) and dermatomyositis (DM) are
inflammatory muscular diseases of unknown etiology. In
the pathogenesis of these diseases, both humoral and cel-
lular immune dysfunction is implicated52.
Patients with PM and DM are classically treated with
steroids. In patients resistant to steroids or in whom their
side effects are unacceptable, other immunosuppressive
agents (cyclophosphamide, cyclosporin), IVIG, total body
irradiation, and PP have been used53. Dau54 was the first
to report on the efficacy of PP in steroid resistant PM and
DM, while in a recent multicenter study of PP in 57 pa-
tients with PM and DM55 the most significant improve-
ment was observed in patients with acute inflammatory
myopathies (but not in subacute or chronic patients).
PP is recommended in PM and DM patients whose
condition continues to worsen in spite of steroid therapy,
and in those who need high steroid doses (to avoid long-
term steroid complications). The PP protocol is twice
weekly for 3 weeks, then weekly for 3 weeks, followed by
a gradual weaning process. Coadministration of ISDT is
important, and consists of low doses of cyclophosphamide,
azathioprine, methotrexate, and prednisolone.
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Saæetak
PLAZMAFEREZA U NEUROLO©KIM BOLESTIMA
P. Kes i V. Ba¹iÊ
Dva desetljeÊa nakon poËetnih ohrabrujuËih rezultata lijeËenja miastenije gravis pomoÊu plazmafereze, neurolo¹ke bolesti
danas su najËe¹Êa indikacija za terapijsku izmjenu plazme. Plazmafereza je korisna metoda u lijeËenju autoimunih neurolo¹kih
bolesti poput Guillain-Barreova sindroma, miastenije gravis i polineuropatije uzrokovane paraproteinima. U nekim drugim
neurolo¹kim bolestima (multipla skleroza, polimiozitis, dermatomiozitis, kroniËna upalna demijelinizirajuÊa polineuropatija)
plazmafereza nije opÊenito prihvaÊeni naËin lijeËenja. Meðutim, u kroniËnim autoimunim bolestima kao ¹to su multipla
skleroza, polimiozitis, dermatomiozitis i kroniËna upalna demijelinizirajuÊa polineuropatija, plazmafereza se preporuËa u bolesnika
u kojih nije do¹lo do pobolj¹anja usprkos terapiji imunosupresivnim lijekovima, te u onih bolesnika u kojih je potrebno smanjiti
dozu kortikosteroida kako bi se izbjegle komplikacije koje mogu nastati zbog dugotrajne terapije. Plazmafereza i imunosupresivni
lijekovi danas su standardna terapija za Eaton-Lambertov sindrom.
KljuËne rijeËi: Plazmafereza; Autoimune bolesti æivËanog sustava, terapija
